PMDA发布日本药典2026年9月第二批草案并公开征求意见
New Japanese Pharmacopoeia Drafts (September 2026) Open for Public Comment
PMDA发布日本药典2026年9月第二批草案,征求意见期为2026年9月1日至11月30日。该批含16个新收载各论、3个天然药物新各论、3个紫外可见对照图谱和4个红外对照图谱。9月首批草案的评议期为9月1日至30日,含G0-7-191、G1-11-191、G5-10-191三项一般信息草案。
The Pharmaceuticals and Medical Devices Agency (PMDA) has published the second set of Japanese Pharmacopoeia (JP) draft texts for September 2026. JP Drafts (September 2026) Part 2The package includes: 16 new monographs, 3 new monographs for natural drugs, 3 ultraviolet-visible reference spectra 4 infrared reference spectra.Comments can be submitted from 1 September to 30 November 2026. For the full list of drafts, the comment form and submission instructions, please visit the PMDA website. JP Drafts (September 2026) Part 1The first set of JP drafts for September 2026 with a public comment period running from 1 to 30 September 2026, is also still available. It contains three new General Information drafts: Concept on the Assessment and Control of DNA Reactive (Mutagenic) Impurities in Chemically Synthesized Drug Substances and Drug Products<G0-7-191> Nitrogen Determination: Combustion Method (Modified Dumas Method)<G1-11-191> Possible Amendments of the Scientific Names of Natural Drugs listed in the JP<G5-10-191>
来源:ECA GMP News · gmp-compliance.org